WEREWOLF THERAPEUTICS INC. - COMMON STOCK

Werewolf Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

07 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1/1b Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid Tumors

01 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights

11 Aug 2022 07:00:03 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

03 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

06 Jun 2022 16:51:01 By Nasdaq GlobeNewswire

Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

10 May 2022 07:00:02 By Nasdaq GlobeNewswire

Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE™ Molecules at AACR 2022 Annual Meeting

08 Apr 2022 13:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Highlights

24 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-124 in Delivering IL-2 Selectively to the Tumor Microenvironment

16 Mar 2022 08:00:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics Announces Upcoming Presentations at AACR 2022 Annual Meeting

15 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at the SVB Leerink Global Healthcare Conference

08 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at the H.C. Wainwright Bioconnect Conference

05 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

Werewolf Therapeutics Added to the Nasdaq Biotechnology Index

14 Dec 2021 16:01:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present Preclinical Data on INDUKINE™ Molecules at the 63rd American Society of Hematology (ASH) Annual Meeting

01 Dec 2021 08:00:02 By Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Third Quarter 2021 Financial Results and Business Update

10 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at Upcoming Conferences in November 2021

08 Nov 2021 08:03:15 By Nasdaq GlobeNewswire

Werewolf Therapeutics Appoints Meeta Chatterjee, Ph.D., to its Board of Directors

28 Oct 2021 16:01:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present Data on its INDUKINE™ Product Candidates at the Society for Immunotherapy of Cancer Annual Meeting

27 Oct 2021 07:30:00 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at Upcoming Next-Gen Cytokine Therapeutics Summit

14 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference

08 Sep 2021 08:00:03 By Nasdaq GlobeNewswire